---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-003370"
form_type: "8-K"
ticker: "LFST"
cik: "0001845257"
company_name: "LifeStance Health Group, Inc."
filed_at: "2022-03-10T23:59:59+00:00"
generated_at: "2026-06-27T00:07:54.183717+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# LifeStance Q4 revenue $190.1M (+61% YoY); net loss $108M; 2022 guidance reaffirmed

## Summary
- Full-year 2021 revenue $667.5M (+77% YoY); net loss $307.2M largely from stock-based compensation.
- Q4 Adjusted EBITDA $11.4M (6.0% of revenue), down 31% YoY; full-year Adjusted EBITDA $49.2M (7.4% of revenue).
- Clinician base grew 55% to 4,790; 415 net adds in Q4 and 1,693 for the full year.
- 2022 guidance: revenue $865-885M, Center Margin $240-255M, Adjusted EBITDA $63-67M.
- Q1 2022 revenue expected $195-200M; Omicron impact estimated at $3-7M; de novo openings moderated to 80-90.

## SEC filing metadata
- accession: 0000950170-22-003370
- form_type: 8-K
- ticker: LFST
- cik: 0001845257
- company_name: LifeStance Health Group, Inc.
- filed_at: 2022-03-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1845257/000095017022003370/0000950170-22-003370-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1845257/000095017022003370/lfst-20220310.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-003370
- JSON: https://secwatch.observer/filing/0000950170-22-003370.json
- Plain text: https://secwatch.observer/filing/0000950170-22-003370.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.